Diabetes

The Diabetes Care Rewards program offers a business case for health plans to promote engagement through use of contingent incentives, thus improving health outcomes and lowering costs.

When comparing 1-step and 2-step approaches for diagnosing gestational diabetes among pregnant women, researchers found no significant between-group differences in the risks of primary outcomes relating to perinatal and maternal complications.

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.

Timing of bout-related moderate-to-vigorous physical activity (MVPA) is associated with cardiorespiratory fitness and cardiovascular risk among men with type 2 diabetes (T2D), independent of bout-related MVPA volume and intensity, according to research published in Diabetes Care.

Medicare Advantage enrollees are more likely to be treated with metformin and sulfonylureas and less likely to receive costly newer medications than those in traditional Medicare.

Collaboration enabled ChristianaCare to significantly grow its population of patients with well-controlled disease, thanks to a diabetes control roadmap that ensured both physical and emotional health needs were met through interprofessional partnerships.

Genetically decreased vitamin D levels are unlikely to have a large effect on risk of type 1 diabetes, according to results of a Mendelian randomization study published in PLOS Medicine.

Low-quality maternal diets may increase the odds of offspring being considered overweight or obese, according to study results published in BMC Medicine.

The SURPASS program, which consists in part of SURPASS-3 and SURPASS-5, is testing the efficacy and safety of tirzepatide, a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the placebo-controlled trial, 86% of participants who received semaglutide attained at least a 5% reduction in total body weight.

On this episode of Managed Care Cast, we speak with experts from ChristianaCare, which implemented a diabetes pilot program at 4 of its primary care sites in 2019 and saw its population of patients with well-controlled disease grow by 16%.

Prediabetes may not be a robust diagnostic biomarker for predicting future diabetes development in older adults.

Results of a prospective cohort study suggest history of gestational diabetes (GD) may promote development of atherosclerotic plaque, potentially increasing the risk of future heart disease among women, even in the absence of hyperglycemia.

There needs to be broad acceptance of the role systemic racism plays in social determinants of health in order to improve metabolic outcomes among minority populations in the United States.

A prospective cohort study found that diabetes and insulin resistance were the strongest risk factors for premature onset of coronary heart disease (CHD) among American women. Results were published in JAMA Cardiology.

Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes (T2D), according to results of a 10-year follow-up study of a randomized controlled trial published in The Lancet.

Results of a vignette-based survey study indicate patients with diabetes require greater health benefits to adopt more intrusive remote digital monitoring (RDM), food monitoring, and real-time feedback by a health care professional.

Results of a phase 2 trial showed that an activin type II receptor blockade, achieved via bimagrumab, led to significant loss of fat mass, gain in lean mass, and metabolic improvements among patients with type 2 diabetes (T2D) and overweight or obesity.

Non-Hispanic Black individuals with type 1 diabetes and coronavirus disease 2019 infections may be more likely to be hospitalized for diabetic ketoacidosis (DKA) compared with non-Hispanic White patients.

A new American Diabetes Association (ADA) survey highlights how the coronavirus disease 2019 (COVID-19) pandemic took a toll on the population with diabetes, which is one of the most prevalent preexisting conditions in America.

The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.

Michael Snyder, PhD, professor and chair of genetics at the Stanford University School of Medicine, discusses the ways in which precision health measurements can aid physicians in detecting and better managing diabetes.

A reduction in glycated hemoglobin (A1C) may result in improved perinatal and maternal outcomes among women with prepregnancy diabetes, according to results of a cohort study published in JAMA Network Open.

Using advanced machine learning models, researchers in China were able to accurately predict incidence of gestational diabetes among pregnant women during their first trimester.

Advancements in coverage for diabetes technology and improvement in diabetic retinopathy screening rates appear on this year’s list of most-read diabetes articles.